Bosuvi is a vital medication for managing resistant or intolerant cases of Ph+ CML, offering hope to patients who have limited options. However, its use requires careful monitoring due to potential side effects and interactions. Bosuvi is an oral tyrosine kinase inhibitor used in the treatment of certain types of leukemia. It is particularly effective in patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) who are resistant or intolerant to prior therapies. Bosuvi works by targeting and inhibiting the BCR-ABL protein, which drives the proliferation of cancer cells in Ph+ CML.

Indications 

Chronic Myeloid Leukemia (CML)

Chronic Phase (CP)

Accelerated Phase (AP)

Blast Phase (BP)

Particularly in patients with resistance or intolerance to prior tyrosine kinase inhibitor therapy.

Bosuvi selectively inhibits the BCR-ABL kinase, the abnormal fusion protein responsible for the progression of Ph+ CML. By blocking this protein, Bosuvi reduces the growth and survival of leukemia cells. It also inhibits other kinases, including Src-family kinases, contributing to its anticancer effects.